Product Name :
Copanlisib dihydrochloride
Description:
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity.
CAS:
1402152-13-9
Molecular Weight:
553.44
Formula:
C23H30Cl2N8O4
Chemical Name:
2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2, 3-dihydroimidazo[1, 2-c]quinazolin-5-yl)pyrimidine-5-carboxamide dihydrochloride
Smiles :
Cl.Cl.COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1
InChiKey:
STGQPVQAAFJJFX-UHFFFAOYSA-N
InChi :
InChI=1S/C23H28N8O4.2ClH/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15;;/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32);2*1H
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I PI3K inhibitor, with IC50s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR.{{Bromhexine} web|{Bromhexine} Autophagy|{Bromhexine} Biological Activity|{Bromhexine} In Vitro|{Bromhexine} supplier|{Bromhexine} Autophagy} Copanlisib dihydrochloride has superior antitumor activity.{{Ranibizumab (anti-VEGF)} MedChemExpress|{Ranibizumab (anti-VEGF)} VEGFR|{Ranibizumab (anti-VEGF)} Protocol|{Ranibizumab (anti-VEGF)} In Vivo|{Ranibizumab (anti-VEGF)} custom synthesis|{Ranibizumab (anti-VEGF)} Autophagy} |Product information|CAS Number: 1402152-13-9|Molecular Weight: 553.44|Formula: C23H30Cl2N8O4|Chemical Name: 2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2, 3-dihydroimidazo[1, 2-c]quinazolin-5-yl)pyrimidine-5-carboxamide dihydrochloride|Smiles: Cl.Cl.COC1=C2N=C(NC(=O)C3=CN=C(N)N=C3)N3CCN=C3C2=CC=C1OCCCN1CCOCC1|InChiKey: STGQPVQAAFJJFX-UHFFFAOYSA-N|InChi: InChI=1S/C23H28N8O4.2ClH/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15;;/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32);2*1H|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 2.PMID:25040798 13 mg/mL (3.85 mM; Need ultrasonic). H2O : 10 mg/mL (18.07 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Copanlisib (BAY 80-6946; 20-200 nM; 24 hours; BT20 breast cancer cells) treatmemnt induces apoptosis in a subset of tumor cell lines that are resistant to Lapatinib and Trastuzumab. Copanlisib (BAY 80-6946; 0.5-500 nM; 2 hours; ELT3 cells) treatmemnt shows complete inhibition of PI3K-mediated AKT phosphorylation in ELT3 cells. Copanlisib potently inhibits cell proliferation in a panel of human tumor cell lines. Copanlisib has mean IC50 values of 19 nM against cell lines with PIK3CA-activating mutations and 17 nM against HER2-positive cell lines, whereas the activity in PIK3CA wild-type and HER2-negative cells is about 40-fold less potent.|In Vivo:|Copanlisib (BAY 80-6946; 0.5-6 mg/kg; intravenous injection; every second day, every third day; for 60 days; athymic nude rats) treatment displays robust antitumor activity in the rat KPL4 tumor xenograft model.|Products are for research use only. Not for human use.|
